Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,466.58 49.05 0.34%
TOPIX 1,169.16 2.57 0.22%
HANG SENG 22,760.24 64.23 0.28%

Mylan Selected As One of the Leading Suppliers to the South African National Department of Health 2013/2014 Antiretroviral



 Mylan Selected As One of the Leading Suppliers to the South African National
             Department of Health 2013/2014 Antiretroviral Tender

  PR Newswire

  JOHANNESBURG and PITTSBURGH, Nov. 29, 2012

JOHANNESBURG and PITTSBURGH, Nov. 29, 2012 /PRNewswire/ -- Mylan Inc. (Nasdaq:
MYL) announced today that its subsidiary in India, Mylan Laboratories Ltd., a
leading manufacturer of antiretroviral (ARV) drugs, has been selected, through
its South African-based subsidiary Mylan (Proprietary) Limited (Mylan
Limited), as one of the leading suppliers of ARV drugs to the South African
National Department of Health for the tender period January 1, 2013 to
December 31, 2014.

Mylan Limited secured a R1.12 billion share, which represents 19.1% of the
R5.9 billion tender value. As a part of this award, Mylan will supply the
South African Government with 31% of the 30 million units of triple therapy
fixed dose combination (FDC) called for in the tender. Mylan is pleased to
support the Government's initiative to move to triple therapy FDC treatment
regimens in South Africa, as such regimens can simplify treatment and improve
patient adherence.

Mylan CEO Heather Bresch commented, "Mylan's mission is to provide the world's
7 billion people access to high quality medicines, including affordable ARVs.
Only through access to these vital medicines can we stem the tide of HIV/AIDS
in South Africa and around the world. This award reinforces Mylan's commitment
to provide high quality advanced drugs to help people suffering from HIV/AIDS
in South Africa, and we are proud to have been selected as a partner to the
South African Department of Health."

"We believe Mylan's selection as a leading supplier to the South African
Government's ARV tender reflects our vertical integration, quality
manufacturing, global scale and proven-track record of being a reliable
partner in supplying affordable ARV medicines across the world. We are pleased
to bring this global scale, quality and reliability to the South African
market and continue our legacy in fighting HIV/AIDS," said Paul Miller,
Managing Director and Vice President of Mylan's South African business.

Mylan supplies ARV drugs to more than 120 countries around the world and
approximately one-third of HIV/AIDS patients receiving treatment in developing
countries depend on a Mylan ARV product. Mylan will be entering the South
African market with a comprehensive portfolio of ARV drugs, consisting of
first- and second-line adult and pediatric therapies, including several dual
and triple FDCs.

Mylan is a global pharmaceutical company committed to setting new standards in
health care. Working together around the world to provide 7 billion people
access to high quality medicine, we innovate to satisfy unmet needs; make
reliability and service excellence a habit, do what's right, not what's easy
and impact the future through passionate global leadership. We offer a growing
portfolio of more than 1,100 generic pharmaceuticals and several brand
medications. In addition, we offer a wide range of antiretroviral therapies,
upon which approximately one-third of HIV/AIDS patients in developing
countries depend. We also operate one of the largest active pharmaceutical
ingredient manufacturers and currently market products in approximately 150
countries and territories. Our workforce of more than 18,000 people is
dedicated to improving the customer experience and increasing pharmaceutical
access to consumers around the world. But don't take our word for it. See for
yourself. See inside. mylan.com

Website: http://mylan.com
Contact: Nina Devlin (Media), +1-724.514.1968, or Kris King (Investors),
+1-724.514.1813
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement